Compare Medpace Holdings Inc (MEDP) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs SAP SE — how do they compare? Medpace Holdings Inc trades at $599.34 (market cap $16.90B), while SAP SE trades at $202.68 (market cap $240.81B). The key difference: SAP SE is far larger — about 14.2× Medpace Holdings Inc's market cap, and SAP SE pays a 1.4% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | SAP | |
|---|---|---|
Market Cap | $16.90B | $240.81B |
Sector | Technology | Technology |
52-Week High | $620.59 | $280.46 |
52-Week Low | $393.42 | $146.38 |
Enterprise Value | $16.52B | $239.52B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.
Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.
SAP stock trades at $203.07, down 2.63% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported strong Q2 2026 revenue growth driven by cloud demand, though it missed EPS estimates. Fundamentals show robust profitability with a 20.41% net income margin and rising cash flow from operations to $9.16B in 2025. Recent news highlights AI and cloud strategy advancements, with shares reacting positively to analyst upgrades and earnings resilience.
The outlook is cautiously optimistic, with a consensus price target of $209.67 offering modest upside. Investment opportunities lie in SAP's cloud transition and AI integration, but risks include execution challenges, margin pressure from investments, and competitive threats. The stock's valuation at a P/E of 27.16 may limit near-term gains if growth slows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
